Bladder Cancer - Results from #120

Complications after neoadjuvant chemotherapy and radical cystectomy for patients with bladder cancer: A propensity score matched analysis. December 9, 2022

Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non-muscle-Invasive Bladder Cancer. December 9, 2022

A Deep Learning Model for Guiding Precision Therapy in Bladder Cancer - Expert Commentary December 8, 2022

The effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy. December 8, 2022

Open vs. robot-assisted radical cystectomy with extracorporeal or intracorporeal urinary diversion for bladder cancer: A pairwise meta-analysis of outcomes and a network meta- analysis of complications by urinary diversion approach. December 8, 2022

Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer. December 8, 2022

Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection. December 7, 2022

Global changes in bladder cancer mortality in the elderly. December 7, 2022

A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy. December 7, 2022

Effect of Tumor Mutation Burden and Immune Infiltrates on Survival in Bladder Cancer - Expert Commentary December 6, 2022

Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. December 6, 2022

A Prospective descriptive one-year study in France of all BCG therapy dispensations for NMIBC. December 6, 2022

Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer. December 6, 2022

Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting December 5, 2022

Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. December 5, 2022

Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer. December 5, 2022

UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer December 2, 2022

Urine Tests for Diagnosing Bladder Squamous Cell Carcinoma - Expert Commentary December 2, 2022

Neoadjuvant immunochemotherapy in the treatment of nonmetastatic muscle-invasive bladder cancer: a systematic review. December 2, 2022

C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy: A Japan Urological Oncology Group study analysis. December 2, 2022

Page 7 of 454

email news signup